If You Invested $1,000 in Keros Therapeutics, Inc. (KROS)
This article analyzes the historical performance of Keros Therapeutics, Inc. (KROS) stock, detailing how a $1,000 investment would have fared over one and five years, alongside yearly returns since 2020. It also provides an overview of Keros Therapeutics, a clinical-stage biopharmaceutical company focusing on TGF-ß pathway biology, highlighting its lead product candidates KER-065 for neuromuscular diseases and elritercept for hematologic disorders, recent pipeline realignment, and a capital return program.
Behavioral Patterns of KROS and Institutional Flows
The article analyzes Keros Therapeutics Inc. (NASDAQ: KROS), highlighting near-term weak sentiment within a broader long-term weak bias, alongside mid-term strength. It identifies a mid-channel oscillation pattern and offers three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, emphasizing risk management and optimizing position sizing.
KROS Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast for Keros Therapeutics, Inc. (KROS), including analyst price targets, stock performance, and financial data. It covers recent stock price movements, historical highs and lows, market capitalization, and upcoming earnings dates. The report also addresses common questions about KROS stock volatility, revenue, net income, and dividend policy.
Price to sales forward of Keros Therapeutics, Inc. – NASDAQ:KROS
This article displays the "Price to sales forward" financial metric for Keros Therapeutics, Inc. (NASDAQ: KROS) from TradingView. The presented data indicates the current value and shows no change or change percentage. The information is sourced from ICE Data Services and FactSet Research Systems Inc.
Keros Therapeutics appoints Anne Prener to board of directors
Keros Therapeutics, Inc. (NASDAQ: KROS) has announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026. Prener brings extensive experience from leadership roles at pharmaceutical companies and venture capital. The announcement comes as Keros shares are near their 52-week low, and InvestingPro suggests the stock is currently undervalued.
Keros Therapeutics Appoints Anne Prener to its Board of Directors
Keros Therapeutics, Inc. announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026. Dr. Prener brings extensive clinical development expertise and executive leadership experience, which will be instrumental as the company advances its pipeline of novel therapeutics for disorders linked to dysfunctional TGF-ß family proteins. Her appointment is expected to support Keros' long-term growth and its mission to deliver meaningful benefits to patients.
Anne Prener joins Keros Therapeutics (Nasdaq: KROS) board with equity package
Keros Therapeutics has appointed Anne Prener, M.D., Ph.D., to its Board of Directors as a Class III director, effective July 1, 2026, with a term running through the 2029 annual stockholder meeting. She will receive an initial stock option award and an initial RSU award, each valued at $150,000 and capped at 0.075% of common shares outstanding, with quarterly vesting over three years, plus an annual cash retainer and ongoing equity awards. Dr. Prener brings extensive biopharmaceutical leadership experience to the board, which Keros expects to be invaluable for advancing its pipeline and corporate strategy.
Keros Therapeutics director Nima sells $28,166 in company stock
Keros Therapeutics director Nima Farzan sold 2,625 shares of company stock worth approximately $28,166 on June 4, 2026, under a pre-arranged trading plan. The sale occurred while the stock was near its 52-week low and had declined significantly over the past six months. InvestingPro provides additional insights for evaluating KROS's investment potential.
Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Keros Therapeutics Inc (KROS), noting its current valuation score is 7.27, ranking 244 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -4.21, and mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
(KROS) Movement Within Algorithmic Entry Frameworks
Keros Therapeutics Inc. (NASDAQ: KROS) is showing a mid-channel oscillation pattern with strong near-term sentiment that could challenge persistent mid and long-term weakness. Algorithmic analysis highlights an exceptional 112.7:1 risk-reward setup targeting a 35.7% gain against 0.3% risk. Institutional trading strategies, including position trading, momentum breakout, and risk hedging, have been generated based on AI models for KROS.
Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS
Madison Avenue Partners LP significantly reduced its stake in Keros Therapeutics (NASDAQ:KROS) by 69.6% in the fourth quarter of 2025. This institutional activity occurred alongside insider selling and a weaker-than-expected quarterly earnings report from Keros Therapeutics. Despite Madison Avenue Partners' reduction, several other institutional investors increased their holdings, with hedge funds and other institutions now owning approximately 71.56% of the stock.
Keros Therapeutics Inc (KROS) Institutional Confidence
This article analyzes the institutional confidence in Keros Therapeutics Inc (KROS), noting its current institutional shareholding score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 16.94% quarter-over-quarter, with James Simons being the largest institutional shareholder. Key institutional holders and their recent activity are detailed.
Keros Therapeutics Inc (KROS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Keros Therapeutics Inc (KROS), highlighting its current price momentum score of 6.27 within the Biotechnology & Medical Research industry. It details the stock's trading range between resistance at $11.46 and support at $9.52, and presents a summary of various technical indicators and moving averages, which collectively indicate a Sell signal for the stock.
Keros Therapeutics Inc (KROS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses the revenue breakdown of Keros Therapeutics Inc (KROS), covering business segments, regional revenue, and profit contribution. It notes that relevant data for these categories have not yet been disclosed by the company. The current stock price of KROS is provided, along with market cap information.
Keros Therapeutics (NASDAQ: KROS) director buys 1,000 shares under 10b5-1 plan
Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of common stock at a weighted average price of $10.19 per share. This open-market transaction was executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, meaning it was pre-scheduled. Following this purchase, Bienaime directly holds 17,592 common shares in the company.
Keros Therapeutics director Charles W. Newton sells $5,521 in shares
Keros Therapeutics director Charles W. Newton sold 550 shares of the company's common stock for a total of $5,521 on June 11, 2026. The sale was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week low. Despite the recent price decline, InvestingPro analysis indicates the stock is undervalued, with Newton still owning 12,665 shares.
Keros Therapeutics director Charles W. Newton sells $5,521 in shares By Investing.com
Charles W. Newton, a director at Keros Therapeutics, Inc. (NASDAQ:KROS), sold 550 shares of the company’s common stock for a total of $5,521. The sale occurred on June 11, 2026, with shares trading between $9.83 and $10.16. Despite the stock being near its 52-week low and down 52% in six months, InvestingPro analysis suggests it is undervalued with a fair value of $13.98.
Keros Therapeutics (KROS) director Newton sells 550 shares in planned trade
Keros Therapeutics director Charles W. Newton sold 550 shares of common stock at a weighted average price of $10.04 per share, a transaction conducted on June 11, 2026, under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Newton directly holds 12,665 shares of Keros Therapeutics common stock. The sale, which ranged from $9.83 to $10.16 per share, is categorized as neutral in filing impact and sentiment.
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 99% Upside
Keros Therapeutics, Inc.'s average price target has been reduced from $21.83 to $20.2 by 5 analysts, with forecasts ranging from $16 to $25 per share. This new target implies a potential upside of approximately 99% based on the June 12 closing price. The consensus rating for the stock remains a "Buy" from 7 analysts.
[144] Keros Therapeutics, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Keros Therapeutics, Inc. (KROS). The filing details the proposed sale of 550 shares of common stock by an individual, acquired through an RSU on May 15, 2026, with an aggregate market value of $5,472.50. The shares are expected to be sold on NASDAQ via UBS Financial Services, Inc.
Keros Therapeutics director Nima sells $28,166 in company stock
Nima Farzan, a director at Keros Therapeutics, sold 2,625 shares of company stock worth $28,166 on June 4, 2026, under a pre-arranged trading plan. This transaction occurred while the stock was trading near its 52-week low and had declined significantly over the past six months. Despite the sale, InvestingPro analysis suggests the stock is currently undervalued.
Insider Sell: Alpna Seth Sells Shares of Keros Therapeutics Inc (KROS)
Alpna Seth, a Director at Keros Therapeutics Inc (KROS), sold 2,625 shares of the company on June 4, 2026. This transaction leaves her with 9,767 shares. Keros Therapeutics is a clinical-stage biopharmaceutical company, and its stock was trading at $10.72 per share on the day of the sale.
Keros Therapeutics director granted RSUs and options | KROS Insider Trading
Keros Therapeutics director Alpna Seth was granted 7,142 restricted stock units (RSUs) and a stock option for 7,433 shares with an exercise price of $10.50, as reported in a recent Form 4 filing. This compensation-related grant means she did not purchase shares on the open market. The RSUs and options have specific vesting schedules tied to continued service, with full vesting by the company’s 2027 annual meeting, and Seth now holds 12,392 common shares and 7,433 options directly.
Keros Therapeutics (NASDAQ: KROS) director receives RSUs and options grant
Keros Therapeutics director Jean Jacques Bienaime received 7,142 restricted stock units (RSUs) and options for 7,433 shares of Common Stock with an exercise price of $10.50 per share. These equity awards are compensation-related and not open-market trades. Following the grant, Bienaime directly holds 16,592 shares of Common Stock, with the RSUs and options vesting over time, subject to his continued service to the company.
Keros Therapeutics (NASDAQ: KROS) director receives RSU and stock option awards
Keros Therapeutics director Mary Ann Gray was granted 7,142 restricted stock units (RSUs) and options for 7,433 shares at an exercise price of $10.50. The RSUs vest by June 3, 2027, or the 2027 annual meeting, while the stock options vest quarterly over 12 months after June 3, 2026, both subject to continued service. Following these awards, Gray directly holds 12,392 common shares of Keros Therapeutics.
Keros Therapeutics (KROS) director sells 2,625 shares under Rule 10b5-1 plan
Keros Therapeutics director Alpna Seth reported an open-market sale of 2,625 common shares at a weighted average price of $10.72 per share on June 4, 2026. The sale, made between $10.60 and $10.89, was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. Following this transaction, Seth directly retains 9,767 shares of Keros Therapeutics.
Keros Therapeutics, Inc. SEC Filing
This article reports on Keros Therapeutics, Inc.'s SEC Form 144 filing, indicating a proposed sale of securities. The document details the filer and issuer information, the nature of the securities to be sold (Common Stock), and their acquisition details, noting a neutral impact and sentiment. The filing also mentions the broker (UBS Financial Services, Inc.) and the exchange (NASDAQ).
Keros Therapeutics (NASDAQ: KROS) backs directors, auditor and pay
Keros Therapeutics (NASDAQ: KROS) stockholders approved all proposals at their 2026 Annual Meeting. Key decisions included the election of Jean-Jacques Bienaimé and Charles Newton as directors, the ratification of Deloitte & Touche LLP as the company's independent auditor for 2026, and an advisory approval of executive compensation. The meeting outcomes reflect shareholder support for the company's governance and compensation practices.
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.83, Implies 107% Upside
Keros Therapeutics, Inc. (KROS) has seen its average 12-month price target adjusted downwards to $21.83 from $22.2, according to estimates from six analysts. Despite the cut, this new target still suggests approximately 107% potential upside based on the June 2nd closing price. The consensus analyst rating for KROS remains "Buy."
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
Keros Therapeutics, Inc. announced that its President and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for Monday, June 8, 2026, at 4:00 p.m. Eastern time, with a live audio webcast and archived replay available online. Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for disorders linked to dysfunctional TGF-ß family protein signaling.
Keros Therapeutics (Nasdaq: KROS) CEO to join Goldman Sachs healthcare fireside chat
Keros Therapeutics announced that its CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 4:00 p.m. ET. The company is a clinical-stage biopharmaceutical firm focusing on therapeutics for dysfunctional signaling of the transforming growth factor-beta family of proteins, with lead candidates rinvatercept and elritercept for serious neuromuscular and hematologic disorders. A live audio webcast and an archived replay of the event will be available through the investors section of the Keros website.
Trading Systems Reacting to (KROS) Volatility
Keros Therapeutics Inc. (NASDAQ: KROS) is experiencing volatility with strong near-term sentiment potentially challenging persistent mid and long-term weakness. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with a multi-timeframe signal analysis to guide traders on entry, target, and stop-loss levels. The article highlights an exceptional 114.7:1 risk-reward setup targeting a 32.8% gain versus a 0.3% risk.
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Keros Therapeutics (KROS) is focusing on its lead neuromuscular program, rinvatercept (KER-065), for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) in 2026. The drug aims to modulate transforming growth factor-beta family signaling to promote muscle growth and repair. Keros plans a Phase II study for DMD in Q3 2026, with initial data in H1 2027, and will discuss Phase II design for ALS with regulators in H2 2026.
Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates
Keros Therapeutics, Inc. (KROS) reported a Q1 loss, missing revenue estimates. The company's financial performance highlights challenges in meeting market expectations for the quarter.
Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles
Keros Therapeutics (KROS:NASDAQ) announced that the initiation of its Phase 2 rinvatercept study for Duchenne muscular dystrophy (DMD) will be delayed from Q2 2026 to Q3 2026 due to procedural regulatory hurdles. Wedbush Securities analyst Yun Zhong reiterated a Neutral rating with a US$16.00 price target, highlighting the delay is primarily operational and regulatory, not specific to Keros or rinvatercept. The company expects to present initial data from the DMD study in 1H 2027 and continues to advance its elritercept program with Takeda in myelofibrosis and myelodysplastic syndrome.
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16
Wedbush has reiterated its Hold rating on Keros Therapeutics (KROS.US) and maintained its target price at $16. This report indicates a continued neutral stance on the company's stock by the analyst firm.
Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan
A director at Keros Therapeutics, Jean Jacques Bienaime, purchased 1,000 shares of common stock in an open-market transaction on May 15, 2026, at a weighted average price of $10.58 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following this purchase, his direct ownership in Keros Therapeutics (KROS) now totals 9,450 shares, though such pre-planned transactions are typically seen as routine rather than strong indicators of company prospects.
Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates
Keros Therapeutics, Inc. (KROS) reported a wider-than-expected loss for the first quarter, posting a loss of $1.39 per share compared to analysts' estimates of $1.15 per share. The company also significantly missed revenue expectations, recording $849,000 against a forecast of $1.15 million. This financial performance has led to a 1.25% drop in stock value as of Thursday morning.
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Truist Financial has reiterated its Buy rating on Keros Therapeutics (KROS.US). This indicates a continued positive outlook from the firm regarding Keros Therapeutics' stock performance and potential.
Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS)
Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, reported a beneficial ownership of 1,360,419 shares of Keros Therapeutics (NASDAQ: KROS). This stake represents 6.90% of the shares outstanding as of March 31, 2026. The Schedule 13G filing indicates shared voting and dispositive power over these shares, classifying Nantahala as an investment adviser and Harkey and Mack as control persons.
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
Keros Therapeutics (KROS) reported a wider-than-expected first-quarter 2026 loss of $1.21 per share and a significant 99.8% year-over-year revenue plunge to $0.4 million, missing analyst estimates. The company's top line was impacted by the absence of license revenues compared to the prior year, with existing revenues primarily from transition services related to its Takeda agreement. Keros is advancing its pipeline, including a phase II study for rinvatercept in DMD and planned phase III studies for elritercept by partner Takeda.
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
Keros Therapeutics (KROS) reported a Q1 loss of $1.21 per share, missing the Zacks Consensus Estimate of a $0.92 loss, and significantly underperformed its earnings from a year ago. The company also missed revenue estimates, posting $0.37 million compared to an expected higher figure. The stock has seen a 41.1% decline year-to-date and currently holds a Zacks Rank #3 (Hold), indicating that shares are expected to perform in line with the market.
Keros Therapeutics 1Q 2026: Revenue $367K, EPS ($1.21) — 10-Q Summary
Keros Therapeutics reported its first-quarter 2026 financial results, with revenue significantly declining to $367K from $211.25M in the prior year, leading to a net loss of $23.71M or ($1.21) diluted EPS. This decline was primarily due to reduced license and milestone income following a partner transaction in 2025. The company also highlighted pipeline advancements for Rinvatercept and the transition of Elritercept development to Takeda.
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
Keros Therapeutics reported a net loss of $23.7 million in Q1 2026, a significant decrease from a net income of $148.5 million in Q1 2025, primarily due to deferred revenue recognition from a Takeda license agreement and reduced R&D expenses. The company's cash and cash equivalents stood at $281.5 million as of March 31, 2026, which is expected to fund operations into the first half of 2028. Keros also highlighted Takeda's plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.
Takeda to advance Keros anemia drug to Phase 3 as Q1 swings to $23.7M loss
Keros Therapeutics reported a net loss of $23.7 million in Q1 2026, a swing from a $148.5 million net income in Q1 2025, primarily due to past Takeda license revenue and reduced R&D expenses. The company announced that its partner, Takeda, plans to advance elritercept into a Phase 3 clinical trial for anemia in myelofibrosis, expanding its potential indication beyond myelodysplastic syndromes. Keros projects its current cash and cash equivalents of $281.5 million will fund operations into the first half of 2028.
Keros (NASDAQ: KROS) swings to Q1 2026 loss as Takeda license boost fades
Keros Therapeutics reported a net loss of $23.7 million in Q1 2026, a significant swing from a net income of $148.5 million in Q1 2025, primarily due to the absence of substantial license revenue from Takeda recognized in the prior year. Revenue plummeted to $0.4 million from $211.2 million, though R&D expenses also decreased as Takeda assumed costs for elritercept. Keros expects its current cash and cash equivalents of $281.5 million to fund operations into the first half of 2028, with Takeda planning a Phase 3 trial for elritercept.
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
Keros Therapeutics reported a net loss of $23.7 million in Q1 2026, a significant decrease from a net income of $148.5 million in Q1 2025, primarily due to revenue recognized from a Takeda license agreement in the prior year and reduced R&D expenses. The company's cash and cash equivalents stood at $281.5 million as of March 31, 2026, which is expected to fund operations into the first half of 2028. Keros also announced that its partner Takeda plans to advance elritercept into a Phase 3 clinical trial for treating anemia in myelofibrosis.
Keros Therapeutics Inc KROS
This page provides an overview of Keros Therapeutics Inc (KROS) stock, showing its current price, market capitalization, and P/E TTM. It includes sections for financial data, discussions, and analysis, and allows users to comment on the stock. The article displays real-time market data with a 15-minute delay and references risk warnings regarding investment products.
(KROS) and the Role of Price-Sensitive Allocations
This article provides an AI-driven analysis of Keros Therapeutics Inc. (NASDAQ: KROS), highlighting a strong near-term sentiment with neutral mid and long-term outlooks. It details institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis indicating support and resistance levels. The analysis emphasizes a significant 112.7:1 risk-reward setup targeting a 29.2% gain.
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts
Nine analysts have given Keros Therapeutics (NASDAQ:KROS) an average rating of "Hold," with a 12-month price target of $21.3333. The company's stock recently traded up 3.3% and has a market cap of $227.39 million. Keros Therapeutics missed analysts' consensus estimates for its last quarterly earnings, reporting ($0.86) EPS against an expected ($0.49).
